Editor’s note: This is a developing news story. Please check back soon for updates.
Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.
After the March 24 release of negative results from the COAST trial, Opthea in consultation with its development funding agreement (DFA) investors accelerated the topline results for the phase 3 ShORe trial, which also investigated sozinibercept combination therapy for wet AMD.
In the global ShORe trial, patients with wet AMD with minimally classic and occult lesions received 2 mg